Abstract
Noscapine is a phthalide isoquinoline alkaloid that easily traverses the blood brain barrier and has been used for years as an antitussive agent with high safety. Despite binding opioid receptors, noscapine lacks significant hypnotic and euphoric effects rendering it safe in terms of addictive potential. In 1954, Hans Lettré first described noscapine as a mitotic poison. The drug was later tested for cancer treatment in the early 1960's, yet no effect was observed likely as a result of its short biological half-life and limited water solubility. Since 1998, it has regained interest thanks to studies from Emory University, which showed its anticancer activity in animal models with negligible toxicity. In contrast to other microtubule-inhibitors, noscapine does not affect the total intracellular tubulin polymer mass. Instead, it forces the microtubules to spend an increased amount of time in a paused state leading to arrest in mitosis and subsequently inducing mitotic slippage/mitotic catastrophe/apoptosis. In experimental models, noscapine does not induce peripheral neuropathy, which is common with other microtubule inhibitors. Noscapine also inhibits tumor growth and enhances cancer chemosensitivity via selective blockage of NF-κB, an important transcription factor in glioblastoma pathogenesis. Due to their anticancer activities and high penetration through the blood–brain barrier, noscapine analogues strongly deserve further study in various animal models of glioblastoma as potential candidates for future patient therapy.
Similar content being viewed by others
References
Altinoz MA, Elmaci I, Ince B, Ozpinar A, Sav AM (2016) Hemoglobins, hemorphins, and 11p15.5 chromosomal region in cancer biology and immunity with special emphasis for brain tumors. J Neurol Surg Part A. 77(3):247-57
Rida PC, LiVecche D, Ogden A, Zhou J, Aneja R (2015) The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications. Med Res Rev. 35(5):1072–1096
Sung B, Ahn KS, Aggarwal BB (2010) Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer Res. 70(8):3259–3268
Singh H, Singh P, Kumari K, Chandra A, Dass SK, Chandra R (2013) A review on noscapine, and its impact on heme metabolism. Curr Drug Metab. 14(3):351–360
Vree TB, van Dongen RT, Koopman-Kimenai PM (2000) Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 54(6):395–398
Boyer EW (2012) Management of opioid analgesic overdose. N Engl J Med. 367(2):146–155
Kamei J (1996) Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm Pharmacol. 9(5–6):349–356
Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC (1998) Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 95(4):1601–1606
Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, Joshi HC (2007) (2007) Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol. 60(6):831–839
Lasagna L, Owens AH Jr, Shnider BI, Gold GL (1961) Toxicity after large doses of noscapine. Cancer Chemother Rep. 15:33–34
Hiser L, Herrington B, Lobert S (2008) Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro. Leuk Lymphoma. 49(8):1603–1609
Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, Van Meir EG, Glass JD, Joshi HC, Archer DR (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res. 10(15):5187–5201
Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D (2008) Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs. 19(6):553–563
Lettre H (1954) Synergists and antagonists of mitotic poisons. Ann N Y Acad Sci. 58(7):1264–1275
Fanara P, Banerjee J, Hueck RV, Harper MR, Awada M, Turner H, Husted KH, Brandt R, Hellerstein MK (2007) Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J Biol Chem. 282(32):23465–23472
Altinoz MA, Del Maestro R, Nalbantoglu J (2002) Noscapine and diltiazem differentially modulate C6 glioma sensitivity to taxol and radiation induced growth suppression in vitro. Neuro-Oncology. In: Abstract of the 10th Biennial Meeting on Canadian Neuro-Oncology, Montreal, Canada, July 2002, p 214
Altinoz MA, Bilir A, Del Maestro RF, Tuna S, Ozcan E, Gedikoglu G (2006) Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol. 65(5):478–484
Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D (2006) Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug. Int J Oncol. 28(5):1121–1130
Newcomb EW, Lukyanov Y, Alonso-Basanta M, Esencay M, Smirnova I, Schnee T, Shao Y, Devitt ML, Zagzag D, McBride W, Formenti SC (2008) Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys. 71(5):1477–1484
Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, Louie SG, Hofman FM, Chen TC (2011) Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett. 312(2):245–252
Qi Q, Liu X, Li S, Joshi HC, Ye K (2013) Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin. 34(7):930–938
Soubannier V, Stifani S (2017) (2017) NF-κB signalling in glioblastoma. Biomedicines. 5(2):e29. https://doi.org/10.3390/biomedicines5020029
Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J (2014) The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis. 6(9):1329–1335. https://doi.org/10.3978/j.issn.2072-1439.2014.08.13
Chougule MB, Patel AR, Jackson T, Singh M (2011) (2011) Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS ONE 6(3):e17733. https://doi.org/10.1371/journal.pone.0017733
Shen W, Liang B, Yin J, Li X, Cheng J (2015) Noscapine increases the sensitivity of drug-resistant ovarian cancer cell line SKOV3/DDP to cisplatin by regulating cell cycle and activating apoptotic pathways. Cell Biochem Biophys. 72(1):203–213
Verma AK, Bansal S, Singh J, Tiwari RK, Kasi Sankar V, Tandon V, Chandra R (2006) Synthesis and in vitro cytotoxicity of haloderivatives of noscapine. Bioorg Med Chem. 14(19):6733–6736
Ajeawung NF, Joshi HC, Kamnasaran D (2013) Investigation of targetin, a microtubule binding agent which regresses the growth of pediatric high and low grade gliomas. J Pediatr Oncol. 1:32–40
Ni R, Kindler DR, Waag R, Rouault M, Ravikumar P, Nitsch R, Rudin M, Camici GG, Liberale L, Kulic L, Klohs J (2019) fMRI reveals mitigation of cerebrovascular dysfunction by bradykinin receptors 1 and 2 inhibitor noscapine in a mouse model of cerebral amyloidosis. Front Aging Neurosci. 11:27. https://doi.org/10.3389/fnagi.2019.00027
Raidoo DM, Sawant S, Mahabeer R, Bhoola KD (1999) Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology. 43(2–3):255–263
Avdieiev S, Gera L, Havrylyuk D, Hodges RS, Lesyk R, Ribrag V, Vassetzky Y, Kavsan V (2014) Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds. Bioorg Med Chem. 22(15):3815–3823. https://doi.org/10.1016/j.bmc.2014.06.046
Nicoletti NF, Erig TC, Zanin RF, Pereira TC, Bogo MR, Campos MM, Morrone FB (2014) Mechanisms involved in kinin-induced glioma cells proliferation: the role of ERK1/2 and PI3K/Akt pathways. J Neurooncol. 120(2):235–244. https://doi.org/10.1007/s11060-014-1549-4
Oliveira MN, Pillat MM, Motaln H, Ulrich H, Lah TT (2018) Kinin-B1 receptor stimulation promotes invasion and is involved in cell-cell interaction of co-cultured glioblastoma and mesenchymal stem cells. Sci Rep. 8(1):1299. https://doi.org/10.1038/s41598-018-19359-1
Munoz JL, Walker ND, Scotto KW, Rameshwar P (2015) Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 367(1):69–75. https://doi.org/10.1016/j.canlet.2015.07.013
Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C (2018) Carbonic anhydrase XII inhibitors overcome P-glycoprotein-mediated resistance to temozolomide in glioblastoma. Mol Cancer Ther. 17(12):2598–2609. https://doi.org/10.1158/1535-7163.MCT-18-0533
Muthiah D, Henshaw GK, DeBono AJ, Capuano B, Scammells PJ, Callaghan R (2019) Overcoming P-glycoprotein-mediated drug resistance with noscapine derivatives. Drug Metab Dispos. 47(2):164–172. https://doi.org/10.1124/dmd.118.083188
He M, Jiang L, Ren Z, Wang G, Wang J (2016) Noscapine targets EGFR(p-Tyr1068) to suppress the proliferation and invasion of MG63 cells. Sci Rep. 6:37062. https://doi.org/10.1038/srep37062
Jiang YW, Cheng HY, Kuo CL, Way TD, Lien JC, Chueh FS, Lin YL, Chung JG (2019) Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro. Environ Toxicol. 34(4):364–374. https://doi.org/10.1002/tox.22691
Cairo MS (2000) Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park). 14(9 Suppl 8):21–31
Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ (2012) Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol. 167(6):1271–1286. https://doi.org/10.1111/j.1476-5381.2012.02067.x
Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 125(9):3347–3355. https://doi.org/10.1172/JCI80007
Chen X, Dang TT, Facchini PJ (2015) Noscapine comes of age. Phytochemistry 111:7–13. https://doi.org/10.1016/j.phytochem.2014.09.008
DeBono A, Capuano B, Scammells PJ (2015) Progress toward the development of noscapine and derivatives as anticancer agents. J Med Chem. 58(15):5699–5727. https://doi.org/10.1021/jm501180v
Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, Joshi HC (2010) A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer. 46(9):1668–1678. https://doi.org/10.1016/j.ejca.2010.02.017
Ajeawung NF, Joshi HC, Kamnasaran D (2013) The microtubule binding drug EM011 inhibits the growth of paediatric low grade gliomas. Cancer Lett. 335(1):109–118. https://doi.org/10.1016/j.canlet.2013.02.004
Suri C, Naik PK (2015) Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer. SAR QSAR Environ Res. 26(6):507–519. https://doi.org/10.1080/1062936X.2015.1070200
Zhou J, Liu M, Aneja R, Chandra R, Joshi HC (2004) Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012. Biochem Pharmacol. 68(12):2435–2441
Zhou J, Liu M, Luthra R, Jones J, Aneja R, Chandra R, Tekmal RR, Joshi HC (2005) EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol. 55(5):461–465
Singh IP, Shah P (2017) Tetrahydroisoquinolines in therapeutics: a patent review (2010–2015). Expert Opin Ther Pat. 27(1):17–36
Aneja R, Vangapandu SN, Joshi HC (2006) (2006) Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog. Bioorg Med Chem. 14(24):8352–8358
Cheriyamundath S, Mahaddalkar T, Reddy Nagireddy PK, Sridhar B, Kantevari S, Lopus M (2019) Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine. Pharmacol Rep. 71(1):48–53. https://doi.org/10.1016/j.pharep.2018.09.002
Martin LTP, Nachtigal MW, Selman T, Nguyen E, Salsman J, Dellaire G, Dupré DJ (2019) Bitter taste receptors are expressed in human epithelial ovarian and prostate cancers cells and noscapine stimulation impacts cell survival. Mol Cell Biochem. 454(1–2):203–214. https://doi.org/10.1007/s11010-018-3464-z
Tomás J, Santos CR, Quintela T, Gonçalves I (2016) "Tasting" the cerebrospinal fluid: another function of the choroid plexus? Neuroscience 320:160–171. https://doi.org/10.1016/j.neuroscience.2016.01.057
Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, McKhann GM, Goodman RR, Fine RL (2006) Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol. 76(1):85–92
Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol. 24(17):7612–7621
Vahabzadeh G, Rahbar-Roshandel N, Ebrahimi SA, Mahmoudian M (2015) Neuroprotective effect of noscapine on cerebral oxygen-glucose deprivation injury. Pharmacol Rep. 67(2):281–288. https://doi.org/10.1016/j.pharep.2014.10.011
Altinoz MA, Elmaci İ (2018) Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones. Nitric Oxide 79:68–83. https://doi.org/10.1016/j.niox.2017.10.001
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declared that thy have no conflict of interest.
Research Involving Human Participants and/or Animals
This study does not involve any human participants and/or animals.
Informed Consent
As this study does not involve any human subjects, informed consents were not needed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Altinoz, M.A., Topcu, G., Hacimuftuoglu, A. et al. Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma. Neurochem Res 44, 1796–1806 (2019). https://doi.org/10.1007/s11064-019-02837-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-019-02837-x